NYSE:ABT

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

Retrieved on: 
Wednesday, April 27, 2022
Comparison, Twitter, Life, Freedom, Hospital, Glucose, Patient, Severe cognitive impairment, LinkedIn, Pharmacy, Technology, Heart, FX, Insulin, FreeStyle, NYSE, AID, Parenteral nutrition, Diabetes, World Diabetes Day, Partnership, Risk, Pharmaceutical industry, Medical device, Public relations, Facebook

"Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders," said Jared Watkin, senior vice president of Abbott's diabetes care business.

Key Points: 
  • "Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders," said Jared Watkin, senior vice president of Abbott's diabetes care business.
  • "We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living."
  • "Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease.
  • We are therefore proud to expand our partners and connectivity to offer more freedom of choice in managing diabetes.

Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App

Retrieved on: 
Monday, April 25, 2022
People, Center, Pain, Spinal cord, Centers for Disease Control and Prevention, Twitter, Life, Chronic pain, Wi-Fi, SCS, Brain, Apple, Neurosphere, DRG, Patient, Spine, LinkedIn, Android, Technology, Communication, Mehta, NYSE, Prevalence, Parenteral nutrition, Facebook, Health, Hyperreflexia, Medical device, Poultry, Neuromodulation

Abbott's NeuroSphere myPath digital health app is designed to allow a person to track and report their pain relief and general well-being.

Key Points: 
  • Abbott's NeuroSphere myPath digital health app is designed to allow a person to track and report their pain relief and general well-being.
  • The NeuroSphere myPath app allows people to closely track and document their pain through a series of surveys taken virtually at baseline and during the trial period through the app.
  • The NeuroSphere myPath app is part of a family of apps Abbott has created under the Neurosphere name, including Neurosphere Virtual Clinic.
  • "Our continued advancement of the NeuroSphere myPath app is part of Abbott's commitment to developing new connected health technology that has the potential to bridge the gap between people and their doctors," said Pedro Malha, vice president, Neuromodulation, Abbott.

Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms

Retrieved on: 
Monday, April 4, 2022
Journal, Life, IDE, LinkedIn, VR, Heart, Arrhythmia, Metal electrode leadless face, BPM, NYSE, Longevity, Food, Health, International Organization (journal), Twitter, Clinical nutrition, American College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Physician, Facebook, ISO, FDA, Patient, Medical device, Electrophysiology

ABBOTT PARK, Ill., April 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.

Key Points: 
  • ABBOTT PARK, Ill., April 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.
  • The Aveir leadless pacemaker is implanted directly inside the heart's right ventricle via a minimally invasive procedure to treat slower-than-normal heart rates.
  • This approval is supported by data from the global LEADLESS II phase 2 investigational device exemption (IDE) study evaluating Aveir VR in patients with certain abnormal heart rhythms.
  • Abbott's Aveir single chamber (VR) leadless pacemaker is approved for the treatment of patients in the U.S. with slow heart rhythms.

(ABT Alert) Long Term Holders of Abbott Laboratories Contact Johnson Fistel for Information Regarding Investigation

Retrieved on: 
Thursday, March 24, 2022
Food, GLOBE, NYSE, Company, LLP, Death, SAN, Abbott Laboratories, Infant

Recently the Food and Drug Administration inspectors found unsanitary conditions at an Abbott Laboratories plant in Michigan that makes infant formula.

Key Points: 
  • Recently the Food and Drug Administration inspectors found unsanitary conditions at an Abbott Laboratories plant in Michigan that makes infant formula.
  • The finding was made five months before the Company conducted a recall of products associated with the deaths of two babies.
  • You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
  • Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws.

Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain

Retrieved on: 
Wednesday, March 30, 2022
New York City Council Black, Latino and Asian (BLA) Caucus, Health equity, Face, Life, Organization, Population, United States Census Bureau, Veteran, Partnership, Contract, NEW, Gaps, Local Initiatives Support Corporation, STEM, Growth, NYSE, LISC, Color, Woman, Black, Global Alliance for Improved Nutrition, Small business, Center for Economic Studies (U.S. Census Bureau), Native, Disability, LGBTQ, Renewable energy, Bank, Health

ABBOTT PARK, Ill., and NEW YORK, March 30, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with the tailored growth capital, loans and support they need to compete, grow and create jobs. The initiative will support greater diversity in the healthcare industry by advancing a more inclusive supply chain for Abbott and other healthcare companies, while contributing to broader economic and health equity.

Key Points: 
  • The initiative will support greater diversity in the healthcare industry by advancing a more inclusive supply chain for Abbott and other healthcare companies, while contributing to broader economic and health equity.
  • The Abbott-LISC Initiative to Support Diverse Businesses in Health aims to break down barriers that prevent diverse small businesses from providing manufacturing and essential products in healthcare.
  • By providing targeted support, Abbott and LISC are working to build a stronger, more diverse healthcare supply chain, as well as healthier local economies and communities.
  • "This partnership is a shared investment in the future of our communities and the strength of our supply chains," said LISC CEO Lisa L. Glover.

Abbott Hosts Conference Call for First-Quarter Earnings

Retrieved on: 
Monday, March 28, 2022
Central, NYSE, Life, Investor relations, EAS (nutrition brand)

ABBOTT PARK, Ill., March 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022, before the market opens.

Key Points: 
  • ABBOTT PARK, Ill., March 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022, before the market opens.
  • The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com .
  • Abbott is a global healthcare leader that helps people live more fully at all stages of life.
  • Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.

Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure

Retrieved on: 
Monday, February 21, 2022
Conditional sentence, Physician, Golf, ESC, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYHA, Natriuresis, HF, Center, Dentistry, IV, American Heart Association, COVID-19, European Society of Cardiology, New York Heart Association Functional Classification, Centers for Disease Control and Prevention, Degenerative disease, NYSE, Disease, Heart failure, Press release, Food, Birdwell, Biomarker, Hospital, International Society of Renal Nutrition and Metabolism, FDA, Pulmonary artery, Pressure, Fatigue, Life, Patient, Quality of life, Walking, Pulmonary hypertension, Time, Pharmaceutical industry, Medical device, Lancet

While heart failure is a chronic disease, medical options like CardioMEMS can provide patients and their doctors with actionable insights to help manage heart failure before it progresses to a later stage.

Key Points: 
  • While heart failure is a chronic disease, medical options like CardioMEMS can provide patients and their doctors with actionable insights to help manage heart failure before it progresses to a later stage.
  • The CardioMEMS HF System was initially approved in 2014 for use in New York Heart Association (NYHA) Class III heart failure patients with a prior heart failure hospitalization within the last year.
  • The new indication allows the CardioMEMS sensor to be used by people living with Class II heart failure and for patients who undergo a blood test showing elevated levels of biomarkers known as natriuretic peptides, which indicate worsening heart failure.
  • Class II heart failure is generally categorized as mild heart failure where patients have a slight limitation with physical activity.

Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant

Retrieved on: 
Thursday, February 17, 2022
NYSE, K8, Parent, Similac, Fever, Environment, Cronobacter, Crying, SH, Infant, Bacteria, Herbalife Nutrition, Cronobacter sakazakii, Child, Multimedia, Caregiver, Life, Vaccine, Medical device

ABBOTT PARK, Ill., Feb. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) is initiating a proactive, voluntary recall of powder formulas, including Similac, Alimentum and EleCare manufactured in Sturgis, Mich., one of the company's manufacturing facilities.

Key Points: 
  • ABBOTT PARK, Ill., Feb. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) is initiating a proactive, voluntary recall of powder formulas, including Similac, Alimentum and EleCare manufactured in Sturgis, Mich., one of the company's manufacturing facilities.
  • Abbott is voluntarily recalling these products after four consumer complaints related to Cronobacter sakazakii or Salmonella Newport in infants who had consumed powder infant formula manufactured in this facility.
  • During testing in our Sturgis, Mich., facility, we found evidence of Cronobacter sakazakiiin the plant in non-product contact areas.
  • No Abbott liquid formulas, powder formulas, or nutrition products from other facilities are impacted by the recall.